Bristol-Myers Squibb Co (BMY) : Huntington National Bank scooped up 78,905 additional shares in Bristol-Myers Squibb Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 25, 2016. The investment management firm now holds a total of 804,645 shares of Bristol-Myers Squibb Co which is valued at $61,531,203.Bristol-Myers Squibb Co makes up approximately 1.50% of Huntington National Bank’s portfolio.
Other Hedge Funds, Including , Butensky Cohen Financial Security Inc reduced its stake in BMY by selling 40 shares or 17.39% in the most recent quarter. The Hedge Fund company now holds 190 shares of BMY which is valued at $14,529. Bristol-Myers Squibb Co makes up approx 0.01% of Butensky Cohen Financial Security Inc’s portfolio.Braver Wealth Management reduced its stake in BMY by selling 1,333 shares or 18.18% in the most recent quarter. The Hedge Fund company now holds 6,000 shares of BMY which is valued at $459,480. Bristol-Myers Squibb Co makes up approx 0.08% of Braver Wealth Management’s portfolio.Needelman Asset Management Inc reduced its stake in BMY by selling 50 shares or 0.34% in the most recent quarter. The Hedge Fund company now holds 14,830 shares of BMY which is valued at $1,094,157. Bristol-Myers Squibb Co makes up approx 3.14% of Needelman Asset Management Inc’s portfolio.
Bristol-Myers Squibb Co opened for trading at $74.57 and hit $75.16 on the upside on Friday, eventually ending the session at $74.81, with a gain of 0.20% or 0.15 points. The heightened volatility saw the trading volume jump to 48,61,139 shares. Company has a market cap of $124,881 M.
On the company’s financial health, Bristol-Myers Squibb Co reported $0.69 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $0.66. The company had revenue of $4881.00 million for the quarter, compared to analysts expectations of $4657.63 million. The company’s revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.53 EPS.
Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. Bristol-Myers Squibb Co was Initiated by Hilliard Lyons to “Neutral” on May 23, 2016. Company shares were Reiterated by UBS on Apr 29, 2016 to “Buy”, Firm has raised the Price Target to $ 80 from a previous price target of $73 .Company shares were Reiterated by Barclays on Apr 29, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 75 from a previous price target of $70 .
Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.